Vx-814    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
231Alpha-1-antitrypsin deficiency5

231. Alpha-1-antitrypsin deficiency    [ 83 clinical trials,   89 drugs,   (DrugBank: 16 drugs),   35 drug target genes,   46 drug target pathways]
Searched query = "Alpha-1-antitrypsin deficiency", "AATD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 83 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-003650-92-SE
(EUCTR)
08/05/202009/12/2019Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZGenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Code: VX-814
INN or Proposed INN: VX-814
Vertex Pharmaceuticals IncorporatedNULLNot RecruitingFemale: yes
Male: yes
43Phase 2United States;Ireland;Netherlands;Germany;United Kingdom;Sweden
2EUCTR2019-003650-92-IE
(EUCTR)
09/04/202010/03/2020Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZGenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Code: VX-814
INN or Proposed INN: VX-814
Vertex Pharmaceuticals IncorporatedNULLNot RecruitingFemale: yes
Male: yes
43Phase 2United States;Ireland;Netherlands;Germany;United Kingdom;Sweden
3EUCTR2019-003650-92-GB
(EUCTR)
28/02/202009/12/2019Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZGenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Code: VX-814
INN or Proposed INN: VX-814
Vertex Pharmaceuticals IncorporatedNULLNot RecruitingFemale: yes
Male: yes
43Phase 2United States;Ireland;Netherlands;Germany;United Kingdom;Sweden
4EUCTR2019-003650-92-DE
(EUCTR)
11/02/202004/12/2019Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZGenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Code: VX-814
INN or Proposed INN: VX-814
Vertex Pharmaceuticals IncorporatedNULLNot RecruitingFemale: yes
Male: yes
43Phase 2United States;Ireland;Netherlands;Germany;United Kingdom;Sweden
5NCT04167345
(ClinicalTrials.gov)
January 13, 202015/11/2019Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ GenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ SubjectsAlpha 1-Antitrypsin DeficiencyDrug: VX-814;Drug: PlaceboVertex Pharmaceuticals IncorporatedNULLTerminated18 Years80 YearsAll48Phase 2United States;Canada;Germany;Ireland